Education
About Us
Working with TipRanks
Follow Us
Lemaitre Vascular (LMAT)
NASDAQ:LMAT
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.66Last Year’s EPS
0.48Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong top-line growth, substantial margin expansion, robust cash generation and confident 2026 guidance while highlighting a successful product launch (Artegraft) and continued geographic expansion. The principal negatives were manageable: a January cyber incident (contained), short-term costs from manufacturing consolidation and a few regulatory timing delays. Overall, the positive operational results, healthy cash position, shareholder returns (buyback and increased dividend), and constructive guidance outweigh the listed challenges.Company Guidance
Strong Q4 and FY2025 Revenue Growth
Q4 sales grew 16% year-over-year; Q4 organic revenue growth was 15% (9% price, 6% units). Full-year 2025 organic revenue growth was 14% (9% price, 5% units). Geographic strength: EMEA +29% in Q4, APAC +20%, Americas +10%.
Expanded Profitability and Operating Leverage
Q4 gross margin rose to 71.7% (+240 basis points YoY) and operating income grew 47% to $18.8M (operating margin 29%). FY2025 adjusted gross margin was 70.4% (+180 bps vs 2024) and adjusted operating margin was 26%.
Earnings Per Share and Cash Generation
Q4 diluted EPS of $0.68 (+39% YoY, including a $0.5M one-time investment mark-to-market loss). Year-end cash and securities totaled $359M; 2025 free cash flow was $74.5M.
Confident 2026 Guidance
Management guided 2026 revenue of $280M (organic growth ~12%), gross margin 72.1%, operating income $77.8M (adjusted +21%), and EPS $2.91 (adjusted +22%). Guidance reflects expected euro-dollar FX of $1.18 and ~4% yield on invested cash.
Successful Product Performance and Launches
Product drivers in Q4: grafts +27%, valvulotomes +20% (17% organic), shunts +18%. RFA vascular +19% and RFA cardiac +90% (small base but rapid growth).
Artegraft Launch Outperformance
Artegraft grew 29% worldwide in Q4. International Artegraft sales were $1.9M in Q4 and $4M for FY2025; company now expects ~ $10M international Artegraft sales in 2026 (management noted an expanded TAM estimate to ~$30M from prior ~$8M). Approvals in 52 countries.
Strategic Capital Allocation and Shareholder Returns
Board approved $100M share repurchase program and raised Q1 2026 dividend to $0.25/share (+25% YoY). This is the 15th consecutive year of dividend increases.
Sales Force and Direct Market Expansion
Company ended 2025 with 160 sales reps (+5% YoY) and plans 170–180 reps by end of 2026. Plans to go direct in Poland (currently ~$650K of annual sales via distributor) and expand direct-to-hospital presence (32nd country).
Regulatory and MDR Progress in Europe
Received final MDR approval for PTFE LifeSpan and broad regulatory progress in Europe supported a strong European performance (FY organic growth in Europe cited at 17%).
LMAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LMAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $91.38 | $113.69 | +24.41% |
Nov 06, 2025 | $85.40 | $86.62 | +1.43% |
Aug 05, 2025 | $85.23 | $92.82 | +8.91% |
May 01, 2025 | $89.63 | $78.17 | -12.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lemaitre Vascular (LMAT) report earnings?
Lemaitre Vascular (LMAT) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Lemaitre Vascular (LMAT) earnings time?
Lemaitre Vascular (LMAT) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LMAT EPS forecast?
LMAT EPS forecast for the fiscal quarter 2026 (Q1) is 0.66.